New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
12:25 EDTDD, STP, FSLR, TSL, CSIQ, JASO, ESLR, YGE, LDK, TEVA, CRL, PC, GILD, YMI, SPWROn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday as investors wait on the Fed and other Washington powers to set the direction. The averages began the session slightly higher and have remained in a narrow range all morning. However, the day's real action may be yet to come, as investors await the conclusion of the two-day Federal Reserve policy meeting. The rate decision is due out at 12:30 pm ET. And, as always, headlines from Washington regarding the fiscal cliff negotiations are always a threat to swing the market quickly in either direction... ECONOMIC EVENTS: In the U.S., import prices fell more than expected and recorded their biggest drop in five months in November, dropping 0.9%. In Europe, the pace of contraction of industrial production in the 17 countries that use the euro accelerated in October, as activity fell 3.6% from a year ago compared to a contraction of 2.8% in September... COMPANY NEWS: DuPont (DD) shares rose 2% after the company said it expects its adjusted EPS to come in at the high end of its previous forecast and also authorized a repurchase program of $1B... A number of solar stocks moved up sharply amid numerous headlines from Chinese and Taiwanese media sources. Reports said China plans additional subsidies for solar companies there and also some China-based makers may sell solar cell equipment to Taiwan. A number of solar names moved higher, including Yingli Green Energy (YGE), up 20%, Trina Solar (TSL), also up 20%, and JA Solar (JASO), up 22%. Additionally, LDK Solar (LDK), which rose 27%, announced it has entered into discussions with certain creditors to obtain additional flexibility as it continues to work to address its previously disclosed liquidity and working capital concerns... MAJOR MOVERS: Among the notable gainers was Panasonic (PC), up almost 8% following an upgrade to Overweight at Barclays. Also higher were shares of YM BioSciences (YMI), up 77% after agreeing to be acquired by Gilead Sciences (GILD) for $2.95 per share in cash. Gilead shares, meanwhile, moved up 10c, or 0.13%. Among the noteworthy losers was Charles River Labs (CRL) down 8% after reaffirming its 2012 guidance and giving guidance for 2013 below Street expectations. Also lower were shares of Teva Pharmaceutical (TEVA), down 4.7% after Leerink downgraded the stock to Market Perform and Wells Fargo removed it from the firm's Priority Stock List... INDICES: Near noon, the Dow was up 8.25, or 0.06%, to 13,256.69; the Nasdaq was down 2.71, or 0.09%, to 3,019.59; and the S&P 500 was up 2.37, or 0.17%, to 1,430.21.
News For DD;YMI;GILD;PC;CRL;TEVA;LDK;YGE;ESLR;JASO;CSIQ;TSL;FSLR;STP;SPWR From The Last 14 Days
Check below for free stories on DD;YMI;GILD;PC;CRL;TEVA;LDK;YGE;ESLR;JASO;CSIQ;TSL;FSLR;STP;SPWR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 14, 2014
11:23 EDTJASOJA Solar raises Q1 shipment view to exceed 620 MW
Earlier today, JA Solar announced preliminary results for its first quarter ended March 31. Based on preliminary financial information, JA Solar currently expects total shipment volume in the 1Q14 to exceed 620 MW, ahead of its previously announced guidance of 580 MW to 610 MW. The company also expects sequential gross margin improvement in 1Q14. Furthermore, the company reiterates its full year cell and module shipments guidance of between 2.7 GW and 2.9 GW, which includes 200 MW of module shipments to the company's downstream projects. "We are proud that solid execution in the quarter enabled us to exceed our previously issued guidance," said Baofang Jin, Chairman and CEO of JA Solar. Shares of JA Solar are trading higher by 7.5% to $10.01 in morning trading.
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
09:09 EDTGILDGilead poised to be leader in all-oral HCV treatment, says Wells Fargo
After attending the EASL conference, Wells Fargo believes that Gilead's HCV treatment has multiple advantages over the competition. The firm keeps an Outperform rating on the stock.
08:15 EDTGILDBristol-Myers submits NDA for Reyataz-cobicistat combo for HIV-1
Bristol-Myers Squibb (BMY) announced the submission of a new drug application, or NDA, on April 4 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is being developed by Gilead Sciences (GILD). Under the terms of a previously announced agreement, Bristol-Myers Squibb and its affiliates are responsible for the formulation, manufacturing, registration, distribution and commercialization of the atazanavir sulfate and cobicistat fixed-dose combination product worldwide. Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
07:59 EDTGILDGilead Sovaldi should take majority share of HCV market, says Stifel
Subscribe for More Information
07:45 EDTGILDAbbVie defended at BMO Capital
Subscribe for More Information
07:37 EDTYGEYingli Green Energy subsidiary to sell at least 300MW solar energy systems
Subscribe for More Information
April 11, 2014
16:03 EDTTSLTrina Solar still sees FY14 module shipments 3.6GW-3.8GW
Subscribe for More Information
16:02 EDTTSLTrina Solar sees Q1 solar module shipments 540MW-570MW had seen 670MW-700MW
Subscribe for More Information
12:04 EDTGILDStocks with call strike movement; AMZN GILD
Amazon.com (AMZN) May 380 call option implied volatility decreased 3% to 43, Gilead (GILD) August 77 call option implied volatility decreased 15% to 45 according to IVolatility.
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
08:58 EDTGILDGilead valuation attractive at current levels, says RBC Capital
Subscribe for More Information
05:25 EDTGILDGilead announces 95% virologic suppression in HCV study
Gilead Sciences announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi 400 mg was administered for the treatment of chronic hepatitis C virus infection in patients with advanced liver disease. The first study, Study GS-US-334-0125, is an ongoing open-label Phase 2 clinical trial evaluating HCV patients with cirrhosis and portal hypertension, with or without decompensation, who were randomized 1:1 to an immediate treatment arm in which Sovaldi and ribavirin was administered for 48 weeks or to a deferred treatment arm in which this regimen was initiated after a 24-week observation period. Eighty percent of participants were treatment-experienced. Of the 22 patients who completed 24 weeks of therapy, 95% achieved virologic suppression on treatment. Additionally, patients taking Sovaldi-based therapy experienced trends in clinical and laboratory parameter improvements compared to patients in the observation arm. Sovaldi-based therapy was well tolerated in the study, and only one patient discontinued treatment due to an adverse event. The most common adverse events occurring in more than 25 percent of patients included nausea and pruritis.
April 10, 2014
13:12 EDTGILDGilead volatility increases on wide price movement
Subscribe for More Information
11:44 EDTGILDStocks with call strike movement; PCLN GILD
Subscribe for More Information
11:42 EDTGILDReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
10:44 EDTFSLRStocks with call strike movement; FSLR LNKD
Subscribe for More Information
07:24 EDTGILDInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information
05:37 EDTGILDGilead announces Phase 2 results for investigational sofosbuvir-based regimens
Gilead Sciences announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, for the treatment of chronic hepatitis C virus, or HCV, infection. The first study, ELECTRON2, is an ongoing, open-label Phase 2 clinical trial evaluating a once-daily fixed-dose combination of SOF 400 mg and the NS5A inhibitor ledipasvir, or LDV, 90 mg, with and without ribavirin, or RBV, twice-daily, among HCV-infected patient populations. In this study, 100% of treatment-na´ve genotype 3 patients receiving 12 weeks of LDV/SOF plus RBV and 64% of treatment-na´ve genotype 3 patients receiving 12 weeks of LDV/SOF without RBV achieved a sustained virologic response 12 weeks after completing therapy. Among genotype 1-infected patients who had failed prior treatment with SOF plus RBV, 100% achieved SVR12 following 12 weeks of LDV/SOF plus RBV. Additionally, 65% of genotype 1-infected patients with decompensated or Child-Turcotte-Pugh Class B cirrhosis receiving 12 weeks of LDV/SOF without RBV achieved SVR12. LDV/SOF with and without RBV was well-tolerated, including among patients with more advanced liver disease. A second study, Study GS-US-342-0102, is an ongoing randomized Phase 2 clinical trial in which treatment-na´ve, non-cirrhotic patients with genotypes 1-6 HCV infection received a 12-week course of SOF plus the pan-genotypic NS5A inhibitor GS-5816. Patients received SOF 400 mg and either GS-5816 25 mg or GS-5816 100 mg. In this study, 94.8% of patients receiving the 25 mg dose of GS-5816 and 96.1% of patients receiving the 100 mg dose achieved SVR12.
05:32 EDTGILDGilead announces results from study of Sovaldi
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use